Aligos Therapeutics, Inc. ALGS
Nov 5, 2026, 12:06 PM EST
- YTD
- -51.18%
- 1 year
- -37.93%
- Market cap
- 28.41M
- Revenue (ttm)
- 6.00M
- EPS (ttm)
- -7.41
- Shares out
- 3.46M
- Forward P/E
- -3.30
- YTD return
- -51.18%
- 1-year return
- -37.93%
- Volume
- 28.10K
- Avg volume
- 68.80K
- Open
- 5.00
- Previous close
- 5.02
- Day's range
- 4.55 – 5.00
- 52-week range
- 3.98 – 13.69
- Beta
- 2.12
- Price target
- 103.33 (+2171.1%)
- Earnings date
- Aug 6, 2024
2Y -5.27 (-53.61%)
Key statistics
- Enterprise value
- 77.15M
- PEG ratio
- 0.00
- Price / sales
- 23.54
- Price / book
- 2.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -60.80%
- Free cash flow
- -49.06M
- Total cash
- 74.92M
- Total debt
- 9.13M
- Return on equity
- -146.69%
- Short % of float
- 12.63%
- 50-day average
- 19.24
- 200-day average
- 16.32
Analyst view
- Target (low)
- 60.00
- Target (mean)
- 103.33
- Target (high)
- 175.00
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -3.67.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -2.15 | -3.07 | -0.92 | -42.79% |
| Aug 6, 2024 | Jun 1, 2024 | -4.00 | 0.75 | +4.75 | +118.75% |
| Aug 6, 2024 | Jun 1, 2024 | -4.00 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -4.75 | -5.50 | -0.75 | -15.79% |
| May 7, 2024 | Mar 1, 2024 | -4.75 | — | — | — |
| Mar 12, 2024 | Dec 1, 2023 | -6.75 | -5.50 | +1.25 | +18.52% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 23, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 19, 2024 | HC Wainwright & Co. | init | — | Buy |
| Jan 17, 2023 | Piper Sandler | main | — | Overweight |
| Jan 6, 2023 | Piper Sandler | up | Neutral | Overweight |
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aligos.com
News
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases 
Aligos Therapeutics Announces Acceptance Of Five Abstracts At American Association For Study Of Liver Disease's The Liver Meeting 
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026 
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session 
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket 
Aligos Therapeutics (NASDAQ:ALGS) & Voyager Therapeutics (NASDAQ:VYGR) Head-To-Head Analysis 
Aligos Therapeutics, Inc. $ALGS Shares Bought by Bank of America Corp DE - 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on ALGS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEIGELMAN LEONID | President | Conversion of Exercise of derivative security | Oct 19, 2020 | 0 |
| BLATT LAWRENCE M | Chief Executive Officer | Stock Award(Grant) | Oct 24, 2023 | 2,120,630 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 19, 2020 | 2,614,560 |
| NUECHTERLEIN CAROLE L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 24, 2023 | 0 |
| SCOPA JAMES PAUL | Director | Stock Award(Grant) | Oct 24, 2023 | 183,083 |
| SYMONS JULIAN A | Officer | Conversion of Exercise of derivative security | Oct 19, 2020 | 394,064 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.78% | 315,095 | 12.40M | Sep 29, 2024 |
| EcoR1 Capital, LLC | 7.12% | 255,573 | 10.05M | Sep 29, 2024 |
| Deep Track Capital, Lp | 6.80% | 244,110 | 9.60M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 6.10% | 218,813 | 8.61M | Sep 29, 2024 |
| Vivo Capital, LLC | 3.95% | 141,879 | 5.58M | Sep 29, 2024 |
| Woodline Partners LP | 2.56% | 91,971 | 3.62M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.47% | 52,795 | 2.08M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.35% | 12,390 | 487.42K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.31% | 11,019 | 433.49K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 4,361 | 171.56K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 3,150 | 123.92K | Oct 30, 2024 |
| Schwab Capital Trust-Total Stock Market Index Fund | 0.03% | 1,255 | 49.37K | Jul 30, 2024 |